Ángel Lucio | CEO
Tetraneuron

I am the CEO of Tetraneuron, a Spanish biotech company, advancing gene therapy solutions for Alzheimer’s disease and other neurodegenerative diseases. After several years supporting the company as an advisor and board member, I now lead its next phase of growth, as we prepare our lead candidate TET101 for first-in-human trials. Over the past 18+ years, I have held leadership roles across Europe and Asia at Johnson & Johnson Innovative Medicine, Takeda, Sanofi, and others, building expertise in business development, M&A, licensing, strategy, and commercial operations. I have led global initiatives across multiple therapeutic areas, successfully bridging science and business to drive innovation. As a seed investor in early-stage biotech and health tech companies, I am committed to supporting transformative ideas that address critical unmet needs. Throughout my career, I have been passionate about turning cutting-edge science into meaningful impact for patients — building ventures that are innovative, global, and purpose-driven. Always open to connecting, collaborating, and pushing the future of healthcare forward.